Background/Aims: Peritoneal fibrosis (PF) is a common complication in patients receiving long-term peritoneal dialysis, which results in damage to peritoneal functions. Epithelial-mesenchymal transition (EMT) is a key step in the early pathogenesis of PF. Increasing evidence has shown that signal transducer and activator of transcription 3 (STAT3) signaling pathway is involved in EMT and tissue fibrosis by interacting with distinct EMT-inducing molecules, including transforming growth factor (TGF)-β and advanced glycation end products (AGEs). This study investigated the involvement of STAT3 in the PF process. Methods: We used high glucose-treated human peritoneal mesothelial cell line HMrSV5 as an in vitro model to expose the peritoneal mesothelial cells to high-glucose dialysate. Expression of EMT markers was detected by qRT-PCR. Accumulation of methylglyoxal (MGO) and AGEs in the culture supernatant were measured by enzyme-linked immunosorbent assay. Phosphorylation of STAT3 was assessed by Western blot. Results: Results showed that high glucose upregulated TGF-β, increased the productions of MGO and AGEs, and induced EMT in HMrSV5 cells. High glucose also activated the STAT3 pathway. STAT3 inhibitor reduced the high glucose-induced EMT, via reducing TGF-β expression and repressing the accumulation of MGO and AGEs. Conclusion: Our results revealed a critical role for STAT3 signaling in high glucose-induced EMT in HMrSV5 cells, and suggested that inhibition of STAT3 might be a treatment for high glucose-induced fibrogenesis in PF.
Introduction
Peritoneal dialysis (PD) is a well-established renal replacement therapy against endstage renal diseases. In this process the peritoneum of the patient is used as the membrane, through which solutes and fluid are exchanged between the dialysate and the blood. Glucose solution is commonly used as the osmotic agent of the dialysate. However, due to the high glucose concentration, dialysate is bio-incompatible [1] . Long-term use of high-glucose dialysate could induce epithelial-mesenchymal transition (EMT) in peritoneal mesothelial cells, leading to peritoneal fibrosis (PF) [2] , which reduces dialysis efficacy and ultimately makes patients withdraw from PD treatment.
One mechanism underlying the high glucose dialysate-induced PF is the accumulation of methylglyoxal (MGO) and advanced glycation end products (AGEs). MGO is a byproduct of glycolysis formed mainly from the degradation of triose phosphates, a tiny "leak" from the glycolysis process [3] . Previous study found that peritoneal injection of MGO accelerated the conventional PD dialysate-induced progression of fibrous peritoneal thickening [4] . MGO was identified as the major precursor of AGEs [5, 6] . Accumulation of AGEs in the interstitium and vessel walls was found to associate with interstitial fibrosis in patients receiving long-term PD [7] . However, mechanism underlying PF induction by MGO and AGEs is not fully studied.
It has been well documented that the signal transducer and activator of transcription 3 (STAT3) signaling pathways are involved in EMT and tissue fibrosis [8] . Activation of STAT3 could induce the expression of the EMT regulator gene SNAIL and thus promote EMT [9, 10] . Previous study showed that the Janus Kinase (JAK)/STAT3 pathway was essential in transforming growth factor (TGF)-β-induced EMT of human lung cancer cell lines [11] . Inhibiting STAT3 activity by paclitaxel was found to attenuate renal interstitial fibrosis in mice with ureteral obstruction [12] . A recent study found that in mouse podocytes, AGEs could activate the STAT3 pathway and exert pro-apoptotic and pro-inflammatory effects [13] . However, it is unclear whether STAT3 pathway is also involved in AGEs mediated PF.
This study aimed to investigate the involvement of STAT3 pathway in the PF process using high glucose-treated human peritoneal mesothelial cells HMrSV5 as an in vitro model.
Materials and Methods

Cell Culture and Treatment
HMrSV5 cells were purchased from Jennio Biotech Co., Ltd. (Guangzhou, China) and maintained in Dulbecco's Modified Eagle's medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco), 100 μg/mL streptomycin and 100 U/mL penicillin. For high glucose treatment, cells were first seeded into cell culture plates. After the cells were attached to the culture plates, cells were treated with phosphate-buffered saline (PBS) or 4.25% glucose for increasing periods of time (24, 48 or 72 h), respectively. To study the role of STAT3 under high glucose condition, cells were co-treated with STAT3 inhibitor BP-1-102 (5 μM, purchased from Selleck, Shanghai, China) and 4.25% glucose for 72 h. Then cells were harvested for further experiments.
qRT-PCR Total RNA was purified by Trizol method (Invitrogen, Waltham, MA, USA). Quantitative RT-PCR was carried out using One Step TB Green PrimeScript Kit (Taraka, Dalian, China). The relative mRNA amount of target gene was normalized to GAPDH, using the 2 -ΔΔCt method. The primers were as follows: vimentin: 5′-TTGAACGCAAAGTGGAATC-3′ and 5′-AGGTCAGGCTTG-GAAACA-3′; N-cadherin, 5′-CGAGCCGCCTGCGCTGCCAC-3′ and 5′-C GCTGCTCTCCGCT CC-C CGC-3′; TGF-β: 5′-AGCAACAATTCCTGGCGATAC-3′ and 5′-CAACCACTGCCGCACAACT-3′; fibronectin (FN): 5′-CGGTGGCTGTCAGTCAAAG-3′ and 5′-AAACCTCGGCTTCCTCCATAA-3′; α-SMA: 5′-CCCTTGAGAAGAGTTACGAGTTG-3′ and 5′-TGATGCTGTTGTAGGTGGTTTC-3′; Ecadherin: 5′-GTCACTGACACCAACGATATTCCT-3′ and 5′-TTTCAGTGTGGTGATTACGAC GTT-3′; GAPDH: 5′-ACACCCACTCCTCCACCTTT-3′ and 5′-TTACTCCTTGGAGGCCATGT-3′.
Assessment of Cell Proliferation and Apoptosis
Cells were treated with 4.25% glucose for increasing periods of time (24, 48 or 72h) , respectively. Then cell apoptosis was measured with an Annexin-V-FITC/PI apoptosis kit (KeyGEN Biotech, Nanjing, China), following by detection using flow cytometric analysis (BD Biosciences, San Jose, CA, USA). Cell proliferation was measured by Cell Counting Kit-8 (CCK-8) assay using a commercial kit (Kumamoto, Japan) following the manual.
Measurement of MGO and AGEs
Cells were treated with 4.25% glucose for increasing periods of time (24, 48 or 72 h), respectively. Then the supernatants were collected, and the concentrations of MGO and AGEs were measured by enzyme-linked immunosorbent assay (ELISA), according to the manuals (kits for MGO ELISA were purchased from HycultBiotech, Netherlands; kits for AGEs ELISA were purchased from Cusabio, Wuhan, China).
Western Blot
Cells were lysed using RIPA buffer. Total protein was extracted and separated by SDS-PAGE. Western blot was carried out using standard method [14] . The primary antibodies were: anti-STAT3 (1: 1,000, Cell Signaling Technology, Danvers, MA, USA), anti-phos-STAT3 (Tyr-705) (1: 1,000, Cell Signaling Technology) and anti-β-actin (as control, 1: 2,000, Abcam).
Statistics
Data were presented as mean ± standard deviation (SD). One-way ANOVA followed by post hoc Tukey's test was carried out to evaluate the differences among groups. t test was used to compare the difference between two groups. p < 0.05 was considered statistically significant.
Results
High Glucose Induces EMT in HMrSV5 Cells
We measured the mRNA levels of several EMT markers, including mesenchymal markers (α-SMA, etc.) and epithelial-specific marker (E-cadherin), to determine the extent of EMT in high glucose-treated HMrSV5 cells. As shown in Figure 1 , compared with PBS-treated cells, the mRNA levels of vimentin (2.639 ± 0.377), N-cadherin (4.367 ± 0.707), TGF-β (1.929 ± 0.103), FN (3.813 ± 0.516) and α-SMA (3.932 ± 0.630) were significantly elevated in high glucose-treated cells, while E-cadherin (0.588 ± 0.083) mRNA expression was significantly reduced. These results indicated that high glucose could induce EMT in HMrSV5 cells.
Effect of High Glucose on Apoptosis and Proliferation of HMrSV5 Cells
As shown in Figure 2 , the percentage of Annexin-V and PI double positive cells (apoptotic cells) was not influenced by high glucose treatment at any time point (7.97 ± 0.17%, 7.79 ± 0.64%, 7.84 ± 0.29%, 7.71 ± 0.20%) (Fig. 2a and b) , showing that high glucose had no effect on cell apoptosis. On the other hand, results of CCK-8 assays showed that the viability of HMrSV5 cells (0.949 ± 0.039) was significantly reduced after 48 h of high glucose treatment (0.808 ± 0.041), and the cell viability was further reduced after 72 h treatment (0.521 ± 0.053) (Fig. 2c) , indicating that high glucose inhibited proliferation of HMrSV5 cells. 
High Glucose Induces Accumulation of MGO and AGEs in the Supernatant of HMrSV5 Cells
MGO is a byproduct of glycolysis and the major precursor of AGEs, which play an important role in EMT. Here we found that the concentrations of MGO and AGEs in the supernatant of high glucose treated cells were significantly increased compared with PBS-treated cells, in a time-dependent manner ( Fig. 3a and b) , indicating that high glucose induced production of MGO and AGEs in HMrSV5 cells.
High Glucose Upregulates STAT3 and phos-STAT3 in HMrSV5 Cells
Results of Western blot showed that the protein levels of STAT3 and phosphorylated STAT3 (Tyr-705) in the cells were significantly increased after 48 h of high glucose treatment, which were further increased after 72 h treatment (Fig. 4a-c) , compared with PBS-treated cells. These results showed that high glucose could activate STAT3 signaling in HMrSV5 cells.
STAT3 Inhibitor Reverses the Effect of High Glucose in HMrSV5 Cells
As shown in Figure 5 , compared with high glucose-treated cells, cells co-treated with STAT3 inhibitor BP-1-102 showed decreased mesenchymal markers (vimentin, α-SMA, etc.) and increased epithelial-specific marker (E-cadherin) (Fig. 5a ), increased cell viability (Fig. 5b) , and decreased concentrations of MGO and AGEs in the cell supernatant ( Fig. 5c and  d) . These results indicated that BP-1-102 could reverse the effect of high glucose in HMrSV5 cells.
Discussion
In this study we sought to investigate the involvement of STAT3 pathway in the PF process. We used high glucose-treated human peritoneal mesothelial cell line HMrSV5 as an in vitro model to expose the peritoneal mesothelial cells to high-glucose dialysate. As expected, we found that high glucose induced EMT in HMrSV5 cells. It was well documented that EMT was the key point in the early pathogenesis of PF associated with PD [15] . Many distinct molecular changes occur during the EMT process, including transcriptional factor activation, expression of specific cell-surface proteins, etc. [16] . Some molecules during this process are used as biomarkers to indicate EMT extent in cells. For example, E-cadherin is an epithelial cell adhesion molecule, and its expression was found to be decreased during EMT in tissue fibrosis [17] . N-cadherin is expressed in mesenchymal cells, and cadherin switch (changes in the expression level) from E-cadherin to N-cadherin has been used to monitor EMT [18] . Upregulated α-SMA and vimentin are classic markers of EMT, and have been used to identify cells in the midst of EMT [15, 16] . FN is a component of extracellular matrix that is associated with tissue fibrosis, and was found to be upregulated during EMT [15] . In this study, we found that the expression pattern of these molecules in high glucose-treated HMrSV5 cells was in accordance with that observed in EMT, demonstrating that high glucose induced EMT in HMrSV5 cells. Meanwhile, we found that the cell proliferation was significantly reduced after treatment with high glucose. This result might be attributed to the conversion of cells from mesothelial cells to fibroblasts, thus resulting in reduced proliferation. TGF-β plays a critical role in PF through inducing EMT. It could downregulate E-cadherin expression via the SNAIL pathway, and induce epithelial cells to lose cell-cell contact [19] . Inhibitor of TGF-β, BMP-7, was found to reverse the TGF-β-induced downregulation of E-cadherin. In vivo data showed that BMP-7 reversed EMT and repaired the damage of epithelial structures in mouse models of renal injury and fibrosis [20] . Previous study found that high glucose could increase TGF-β activity through Smad2 acetylation [21] . Moreover, high glucose might also stimulate the synthesis of TGF-β through the formation of AGEs [15, 22] . AGEs are mainly formed from MGO, a byproduct of glycolysis, and are found to play an important role in EMT [23] . Studies showed that AGEs could bind to the AGE receptors on the cell membrane of rat kidney epithelial cells, and induce the expression of TGF-β which promoted EMT [24] . In this study we found that high glucose treatment resulted in increased TGF-β expression, along with increased MGO and AGEs concentrations, demonstrating that high glucose could promote EMT via inducing AGEs and TGF-β.
Increasing evidence has shown that the STAT3 signaling pathways are involved in EMT and tissue fibrosis. STAT3 is a transcription factor, whose transcriptional activity is positively regulated by phosphorylation at the Tyr705 residue by JAKs [25] . Previous study showed that the activation of JAK/STAT3 pathway was required in TGF-β-induced EMT of human lung cancer cell lines [11] . Activation of JAK/STAT3 pathway was also associated with liver fibrosis in mouse models [26] . Upregulation of phosphorylated STAT3 at Tyr705 was observed in a rat model of renal fibrosis [27] . In accordance with these results, we found that high glucose treatment resulted in upregulation of phosphorylated STAT3 at Tyr705 in HMrSV5 cells, indicating that high glucose induced EMT in these cells via activating the STAT3 pathway. To further verify the involvement of STAT3 in this process, we examined the effect of STAT3 inhibition in high glucose-induced EMT. BP-1-102 is a phospho-tyrosine mimic that could bind the STAT3-SH2 domain and thus block the phosphorylation of STAT3 at Tyr residues [28] . We found that BP-1-102 reduced the expression of TGF-β and suppressed EMT after high glucose treatment. Our results were consistent with a previous study, which showed that treatment with S3I-201 (another STAT3 inhibitor that diminishes STAT3 tyrosine phosphorylation) inhibited the expression of α-SMA, reduced the deposition of extracellular matrix proteins and attenuated renal fibrosis [25] . It is interesting that in this study, we found BP-1-102 reduced the concentrations of MGO and AGEs after high glucose treatment. It was well documented that AGE could induce the activation of the STAT3 pathway to exert biological functions [13, 29] . However, the mechanism responsible for STAT3 pathway regulation on the production of MGO and AGEs remains unclear, which requires further investigation.
Conclusions
In conclusion, our current study demonstrates that high glucose induces EMT in HMrSV5 cells via upregulating TGF-β and increasing the production of MGO and AGEs. High glucose also activates the STAT3 pathway. Treatment with STAT3 inhibitor reverses the high glucoseinduced changes in EMT markers and thus reduces EMT, indicating that the effect of high glucose in inducing EMT is mediated by the STAT3 pathway.
